Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YinQiaoSan is a classic Traditional Chinese Medicine (TCM) herbal formula originally documented in the 18th-century text *Wen Bing Tiao Bian* (Systematic Differentiation of Warm Diseases). It is a multi-component botanical product traditionally used to treat "wind-heat" patterns, which clinically manifest as fever, sore throat, and cough. The formula typically consists of ten ingredients: *Lonicera japonica* (honeysuckle), *Forsythia suspensa*, *Platycodon grandiflorus*, *Mentha haplocalyx*, *Lophatherum gracile*, *Glycyrrhiza uralensis* (licorice), *Schizonepeta tenuifolia*, *Glycine max* (fermented soybean), *Arctium lappa*, and *Phragmites communis*. In modern clinical research, YinQiaoSan is investigated for its efficacy in treating respiratory viral infections, including influenza and COVID-19. Its mechanism of action is characterized by anti-inflammatory, immunomodulatory, and antiviral effects, often involving the downregulation of pro-inflammatory cytokines and interference with viral replication pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on YinQiaoSan.